Novartis Touts Galvus Efficacy Vs. Januvia After Metformin Comparison Fails
Executive Summary
Novartis is highlighting the superior efficacy of its dipeptidyl peptidase-4 inhibitor Galvus relative to Merck's recently launched DPP-4 agent Januvia.
You may also be interested in...
Galvus “Approvable”: Additional Trial To Be Relatively Small, Short – Novartis
FDA will likely require Novartis to conduct a clinical trial of the dipeptidyl peptidase-4 inhibitor Galvus in a relatively small number of patients that are predisposed to achieving high plasma levels with standard doses of the drug, Novartis Global Pharma Development Head James Shannon said
Galvus “Approvable”: Additional Trial To Be Relatively Small, Short – Novartis
FDA will likely require Novartis to conduct a clinical trial of the dipeptidyl peptidase-4 inhibitor Galvus in a relatively small number of patients that are predisposed to achieving high plasma levels with standard doses of the drug, Novartis Global Pharma Development Head James Shannon said
AstraZeneca Cuts 3,000 Manufacturing Jobs, Pares Down Therapeutic Areas
AstraZeneca's focus on improving manufacturing efficiencies, on the heels of similar moves by Merck and Pfizer, may signal that manufacturing is the next target for industry cost-cutting initiatives